Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Profit After Tax data on record, last reported at $24.4 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 35.65% year-over-year to $24.4 million; the TTM value through Dec 2025 reached $98.1 million, down 38.51%, while the annual FY2025 figure was $98.1 million, 38.51% down from the prior year.
  • Profit After Tax reached $24.4 million in Q4 2025 per AMPH's latest filing, up from $17.3 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $49.2 million in Q3 2023 and bottomed at $5.0 million in Q1 2021.
  • Average Profit After Tax over 5 years is $27.4 million, with a median of $26.1 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: surged 4145.31% in 2021, then tumbled 57.09% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $18.6 million in 2021, then skyrocketed by 82.57% to $33.9 million in 2022, then increased by 6.65% to $36.2 million in 2023, then rose by 4.97% to $38.0 million in 2024, then tumbled by 35.65% to $24.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $24.4 million in Q4 2025, $17.3 million in Q3 2025, and $31.0 million in Q2 2025.